AI English summary of an SEC filing — figures as filed
West Pharmaceutical Services WSTWest Pharmaceutical said consolidated net sales for the 3 months ended September 30, 2026 rose $69.9 million, or 8.7%. Excluding an unfavorable foreign currency translation impact of $4.0 million and the $18.0 million reduction in SmartDose 3.5mL product revenue, organic growth was $91.9 million, or 11.9%.
Key points
AI summaryWest Pharmaceutical said consolidated net sales for the 3 months ended September 30, 2026 rose $69.9 million, or 8.7%. Excluding an unfavorable foreign currency translation impact of $4.0 million and the $18.0 million reduction in SmartDose 3.5mL product revenue, organic growth was $91.9 million, or 11.9%.
The company said it sold its SmartDose 3.5mL On-Body Delivery System assets to AbbVie and recorded a net benefit of $55.7 million within other expense (income) in Q3 2026. It said it also recorded a one-time tax cost of $22.4 million related to the sale.
The company said consolidated gross profit for Q3 2026 increased $53.1 million, or 18.0%, and consolidated gross profit margin rose 3.1 percentage points. Consolidated operating profit grew $99.8 million, or 59.5%. Proprietary Products operating profit increased $55.4 million.
West Pharmaceutical said operating cash flow for the 9 months of 2026 decreased $100.3 million from the prior-year period, and net cash used in financing activities increased $541.9 million. It said it repurchased 2,424,121 shares for $685.3 million, at an average price of $282.68 per share.
Summary
AI-writtenAnalysis scope · Management's discussion (MD&A)We analyzed the Management's Discussion and Analysis (MD&A) section. Other sections of the report, such as the notes to the financial statements and risk factors, were not reviewed.
West Pharmaceutical Reports Higher Consolidated Net Sales for Q3 2026
West Pharmaceutical said consolidated net sales for the 3 months ended September 30, 2026 rose $69.9 million, or 8.7%. Excluding an unfavorable foreign currency translation impact of $4.0 million and the $18.0 million reduction in SmartDose 3.5mL product revenue, organic growth was $91.9 million, or 11.9%.
Source · Based on the MD&A text of the filing
SmartDose 3.5mL Asset Sale Gain and Tax
The company said it sold its SmartDose 3.5mL On-Body Delivery System assets to AbbVie and recorded a net benefit of $55.7 million within other expense (income) in Q3 2026. It said it also recorded a one-time tax cost of $22.4 million related to the sale.
Source · Based on the MD&A text of the filing
Gross Profit and Operating Profit Changes for Q3
The company said consolidated gross profit for Q3 2026 increased $53.1 million, or 18.0%, and consolidated gross profit margin rose 3.1 percentage points. Consolidated operating profit grew $99.8 million, or 59.5%. Proprietary Products operating profit increased $55.4 million.
Source · Based on the MD&A text of the filing
9-Month Cash Flow and Share Repurchases
West Pharmaceutical said operating cash flow for the 9 months of 2026 decreased $100.3 million from the prior-year period, and net cash used in financing activities increased $541.9 million. It said it repurchased 2,424,121 shares for $685.3 million, at an average price of $282.68 per share.
Source · Based on the MD&A text of the filing
Structured SEC financial data for this filing is not available yet. Please check the figures in the SEC filing.
AI summarized the filing and translated the summary into English; it may differ from the original. For reference only, not investment advice. AI translated the published Korean report into English. Figures are copied as filed, not recalculated.
Original filing
The filing as submitted to SEC EDGAR. You can check the figures and statements of this summary against it.
Loading the filing text…